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Abstract
The emergence of castrate-resistant prostate cancer (CRPC) contributes to the high mortality of patients diagnosed with
prostate cancer (PCa), which in part could be attributed to the existence and the emergence of cancer stem cells (CSCs).
Recent studies have shown that deregulated expression of microRNAs (miRNAs) contributes to the initiation and
progression of PCa. Among several known miRNAs, let-7 family appears to play a key role in the recurrence and progression
of PCa by regulating CSCs; however, the mechanism by which let-7 family contributes to PCa aggressiveness is unclear.
Enhancer of Zeste homolog 2 (EZH2), a putative target of let-7 family, was demonstrated to control stem cell function. In
this study, we found loss of let-7 family with corresponding over-expression of EZH2 in human PCa tissue specimens,
especially in higher Gleason grade tumors. Overexpression of let-7 by transfection of let-7 precursors decreased EZH2
expression and repressed clonogenic ability and sphere-forming capacity of PCa cells, which was consistent with inhibition
of EZH2 39UTR luciferase activity. We also found that the treatment of PCa cells with BR-DIM (formulated DIM: 3,39-
diindolylmethane by Bio Response, Boulder, CO, abbreviated as BR-DIM) up-regulated let-7 and down-regulated EZH2
expression, consistent with inhibition of self-renewal and clonogenic capacity. Moreover, BR-DIM intervention in our on-
going phase II clinical trial in patients prior to radical prostatectomy showed upregulation of let-7 consistent with down-
regulation of EZH2 expression in PCa tissue specimens after BR-DIM intervention. These results suggest that the loss of let-7
mediated increased expression of EZH2 contributes to PCa aggressiveness, which could be attenuated by BR-DIM
treatment, and thus BR-DIM is likely to have clinical impact.
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Introduction
Prostate cancer (PCa) is the second leading cause of cancer
death in men in the United States killing over 32,050 men in 2010
[1]. In the past ten years, there have been significant improve-
ments in the surgical treatment options for patients diagnosed with
localized PCa. Prostate surgery has also benefited from technical
and technological advancements such as nerve sparing prostatec-
tomy and robotic prostatectomy. Adjuvant therapy, defined as
additional treatment to reduce or eliminate local and distant
disease, is offered to patients [2], especially those who are at high
risk of recurrence (as often defined by the d’Amico criteria of PSA
.20 ng/mL, Gleason 8–10, and stage T2c to T4) [3].
Radiation therapy and systemic therapy especially androgen
deprivation therapy (ADT) are considered as reasonable adjuvant
therapeutic options. Patients in the high-risk category have a
recurrence rate of greater than 50% within their lifetime, which is
unacceptable. However, one of the concerns in offering adjuvant
therapy to all patients in the high risk group is that although
greater than 50% of patients do recur, there are 38–50% of
patients who do not [4]. To reduce the burden of over-treatment
in this patient group, additional tools are needed to identify the
truly high-risk patients. Current tools being studied include
predictive nomograms [5] and studies evaluating gene expression
profiling, which have identified a few markers of tumor
aggressiveness [6,7] although such findings have not been
translated to patient management.
Since tumor recurrence and metastasis contribute to the high
mortality, studies have suggested that the aggressiveness of PCa
could be tightly linked with the acquisition of cancer stem cells
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evidence suggests that deregulated expression of many microRNAs
(miRNAs) including the let-7 family contributes to cancer
progression and recurrence [8]. MicroRNAs are a class of non-
coding RNAs of approximately 20 to 22 nucleotides in size. They
regulate gene expressions post-transcriptionally by binding to a site
in the 39untranslated region (39 UTR) of target mRNA. They have
been demonstrated to regulate cell cycle, and development and
progression of cancer [9]. Let-7 was first discovered and well
studied in Caenorhabditis elegans. The human let-7 family consists
of let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g, let-7i and miR-
98. The let-7 family is commonly viewed as a tumor suppressor
consistent with down-regulation of oncogenes such as Ras [10],
high mobility group A2 (HMGA2) [11] and c-myc [12] by binding
to 39UTR of these target mRNAs. Moreover, decreased let-7
expression was found in many cancers, including PCa [13], and it
has been linked with poor patient prognosis in lung cancer [14],
head and neck squamous cell carcinoma [15], and ovarian cancer
[16].
Interestingly, let-7 family members have been demonstrated to
regulate the self-renewal capacity of breast cancer cells [17] and
PCa cells by regulating stem cell-associated factors such as Oct4,
Sox2, and Nanog expression [18]. Recent studies have also
documented that let-7 could regulate the expression of Lin28 and
Lin28B, which in turn block the accumulation of mature let-7
[19]. This feedback regulation plays a critical role in regulating
‘‘stemness’’ by controlling self-renewal [20–23], which is the
cellular characteristic of CSCs or CSLCs associated with tumor
aggressiveness and recurrence. These results suggest that the let-7
family could play a key role in the progression of PCa by
maintaining and regulating molecular features of CSCs or CSLCs
in PCa; however, how let-7 family contributes to PCa aggressive-
ness is unknown.
Enhancer of Zeste homolog 2 (EZH2) is one of the targets of the
let-7 family of miRNAs, and that the expression of EZH2 is
strongly associated with molecular features of both normal stem
cells and CSCs or CSLCs. EZH2 is a histone-lysine N-
methyltransferase, a subunit of polycomb repressive complex 2
(PRC2). The polycomb group of proteins are known to be
involved in the regulation of gene repression through chromatin
modifications, which is essential for the maintenance of the
embryonic and adult stem cells [24,25]. PRC2 contains EZH2,
Suz12, EED, and RbAp subunits and this complex is known to
function in the embryonic and adult stem cells to repress
developmental genes that are preferentially activated during
differentiation [26]. Moreover, further studies have shown that
PRC2 target genes are co-occupied by stem cell regulators such as
Oct4, Sox2, and Nanog [27]. Recent studies have also suggested
that polycomb group proteins are not only essential for embryonic
development but also plays critical roles in tumor initiation and
progression [25]. Over-expression of EZH2 has been strongly
linked with cancer progression partly because PRC2 inhibits E-
cadherin expression, which promotes epithelial-to-mesenchymal
transition (EMT) in cancer cells [28], a phenomenon that is
reminiscent of CSCs or CSLCs. Suz12 has been found to mediate
E-cadherin inhibition by snail1 [29]. More importantly, EZH2
directly regulates DNA methylation by serving as a recruitment
platform for DNA methyltransferase [30]. In our previous study,
we found that the levels of EZH2 and Suz12 mRNA were
increased in PC3 PDGF-D cells (EMT-phenotypic cells) compared
to PC3 Neo cells [18]. These results clearly suggest that PRC2 can
contribute to EMT characteristics of PC3 PDGF-D cells, which
are consistent with signatures of CSCs or CSLCs that are
associated with cancer progression and recurrence.
Previous pre-clinical studies from our laboratory have shown
that indole-3-carbinol (I3C) found in cruciferous vegetables and its
in vivo metabolite 3,39-diindolylmethane (DIM) especially the
formulated DIM (BR-DIM or B-DIM) that we have used for our
phase I clinical trial [31], are potent agents in inhibiting the
growth of PCa cells, which was mediated by alterations in multiple
cellular signaling [32]. Our recent results showed that BR-DIM
caused upregulation of miR-200b and miR-200c that are typically
lost in PCa cells [33]. In the current study, we found loss of
expression of let-7 family consistent with over-expression EZH2 in
PCa cells and in human PCa tissue specimens, especially in tumors
with higher Gleason grade. The results from correlation analysis
showed that let-7 expression was inversely associated with EZH2
expression in patients with higher Gleason grade tumors. Here we
also provide evidence for the role of BR-DIM (formulated DIM:
3,39-diindolylmethane, abbreviated as either BR-DIM or B-DIM)
in the regulation of let-7 and EZH2 in PCa cells as documented by
our pre-clinical findings as well as findings from our on-going
phase II clinical trial in PCa patients received BR-DIM prior to
radical prostatectomy.
Materials and Methods
Cell lines and culture condition
LNCaP, C4-2B, and CWR22RV1 were maintained in RPMI
1640 (Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum (FBS), 10 mmol/L Hepes, 50 units/ml Penicillin and
50 mg/ml Streptomycin. Stable cell lines over-expressing PDGF-D
and empty vector pcDNA3 were generated by transfection of PC3
cells with the pcDNA3-PDGF-D:His or corresponding empty
vector pcDNA3 Neo as previously described and referred to as
PC3 Neo, or PC3 PDGF-D cells [34], respectively throughout this
manuscript. The PC3 Neo, PC3 PDGF-D, PC3, DU145 cells were
cultured in RPMI 1640 medium with 2 mmol/L glutamine,
10 mmol/L Hepes (Invitrogen, Carlsbad, CA) supplemented with
5% fetal bovine serum (FBS), 50 units/ml Penicillin, and 50 mg/ml
Streptomycin. PZ-HPV-7 and RWPE-1 cells were purchased from
ATCC (Manassas, VA). These cells were cultured in keratinocyte
serum free medium (K-SFM) provided by Invitrogen (GIBCO)
and supplied with 0.05 mg/ml bovine pituitary extract (BPE) and
5 ng/ml human recombinant epidermal growth factor (EGF). All
cells were maintained in a 5% CO2-humidified atmosphere at
37uC, and genotypically characterized to support the authenticity
of these cells, which was consistent with its origin.
Reagents and antibodies
Antibody against EZH2 was purchased from BD Biosciences
(Bedford, MA). Antibody to glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) was purchased from Affinity BioReagents
(Golden, CO). Goat anti-mouse IgG (H+L)-HRP conjugate were
obtained from Bio-Rad (Reinach, BL). BR-DIM, a formulated
DIM with higher bioavailability, was kindly provided by Dr.
Michael Zeligs (abbreviated as BR-DIM or B-DIM; Bio Response,
Boulder, CO) and was dissolved in DMSO to make 50 mmol/L
stock solutions and stored at 220uC in multiple aliquots for in vitro
study.
Ethics statement
Patient tissues were collected after receiving the approval from
Wayne State University Institutional Review Board (IRB). This
clinical protocol is classified as exempt #4 categories under the
NIH policy because such studies are retrospective studies using
archival sample. The IRB waived the need for consent for use of
the archive samples, which was consistent with NIH guidelines,
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specimens from our on-going clinical trial of BR-DIM (B-DIM)
intervention prior to radical prostatectomy were also obtained
after receiving approval from Wayne State University Institutional
Review Board (IRB) and informed consents were obtained from all
study subjects. Because this study is a conventional clinical trial,
the IRB process required written consenting from patients prior to
accrual into the clinical trial, which is routinely coordinated
through the clinical trial office (CTO). The approval through IRB
implicates complying with consenting and accrual without which
patients cannot be enrolled into the study, and thus our study
fulfilled all the required compliance guidelines from the CTO and
the IRB. The local clinical trial protocol number is 2007-128,
which can be found in the NIH clinical trials.gov. (http://
clinicaltrials.gov/show/NCT00888654). At the time of sample
acquisition for the current investigation, the study protocol
accrued 20 patients; however, the study has now accrued a total
of 33 patients. It is anticipated that we will close this study with 37
patients in early 2012.
Patients and prostate tissue specimen collection
After obtaining institutional review board approval, retrospec-
tive archival pre-treatment PCa tissues and matched adjacent
normal tissues were obtained from Biospecimen Core of
Karmanos Cancer Institute (KCI) collected from patients who
underwent radical prostatectomy from 2004–2010 at KCI. We
also obtained PCa tissue specimens from our on-going clinical trial
of BR-DIM (B-DIM) intervention prior to radical prostatectomy of
newly diagnosed PCa patients from 2009–2011 at KCI and Henry
Ford Health System (HFHS), Detroit, Michigan. Formalin-fixed
paraffin-embedded (FFPE) tissues were cut for miRNA and
mRNA analysis. Patients’ clinical characteristics were obtained
from the hospital database including race as shown in Table 1.
Pathological features were ascertained from microscopic evalua-
tion of tumor slides by pathologists both at KCI and at HFHS.
Gleason score (grade) was obtained in each case from the clinical
database.
Clonogenic assay
C4-2B, PC3 PDGF-D, and PC3 PDGF-D cells transfected with
the let-7 family for 24 h were collected after trypsinization, and re-
suspended in the complete medium. Single cell suspensions were
plated in regular 10 cm in diameter Petri dishes at the colony
density of 2,000 cells per dish. After 2–3 weeks of incubation with
changing fresh media every 3–4 days, colonies were stained with
crystal violet for an additional 10 min, and washed with 16PBS.
The colonies were photographed.
Soft agar assay
C4-2B cells were harvested and suspended in culture medium.
Soft agar assay was performed as previously described by our
laboratory [18]. The cells were treated with 10 or 25 mM BR-DIM
with changing fresh media with BR-DIM every 3 days. After three
weeks of growth, the colonies were stained by incubating with
0.5 mg/ml MTT for 4 hours, and then were photographed (406).
The colony numbers were counted under a phase contrast
microscope. Data were presented as colony numbers (% control).
Self-renewal capacity assay
Single cell suspensions of C4-2B and PC3 PDGF-D cells were
plated in ultra low adherent wells of 6-well plates (Corning,
Lowell, MA) at 2000 cells/well in DMEM/F12 (Invitrogen)
containing 16 B27 and N2 (Invitrogen). Single cell status was
confirmed under microscope. Fresh medium with 10 or 25 mM
was added every 3–4 days. After one week, numbers of prosta-
spheres were counted under a microscope and data were
presented as sphere numbers per 1000 cells seeded. Prostaspheres
were photographed (406) under a phase contrast microscope.
Western blot analysis
Total cell lysates were obtained by lysing the cells in RIPA
buffer. Protein concentration was determined using BCA protein
assay (Pierce, Rockford, IL). Western blotting was performed as
previously described [35].
Table 1. Characteristics of the 129 patients who underwent radical prostatectomy (RP) and the 11 patients in the BR-DIM
intervention group from whom normal and tumor specimens were obtained.
Characteristics Patients who underwent RP (N=129) Patients who took BR-DIM prior to surgery (N=11)#
Age (years), median (range) 59 (45–78) 59.5 (47–64)
Gleason score
6 44 (34.1%) 3 (27.3%)
7 52 (40.3%) 6 (55.5%)
$8 33 (25.6%) 2 (18.2%)
PSA* (pre-intervention)
ng/ml, median (range) 6.5 (1.1–153) 8.15 (3.2–29.14)
Race
African American 78 (60.5%) 5 (45.5%)
European American 51 (39.5%) 4 (36.4%)
Other 0 (0%) 2 (18.1%)
*Pre-intervention PSA was available from 88 of the 129 patients who underwent RP and from 10 of the 11 patients who underwent BR-DIM intervention.
#Data for Gleason score and PSA levels were reported previously (Kong et at. Am J Transl Res 2012; 4(1): 14–23) and showed here for comparison with data from
patients who underwent RP.
doi:10.1371/journal.pone.0033729.t001
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Cells were transfected with 40 nmol/L of let-7 precursors or
miRNA precursors negative control#1 (Ambion, Austin, TX)
using DharmaFECT3 transfection reagent (DHARMACON,
Lafayette, CO). After 1 day of transfection, the cells were
trypsonized, and re-suspended in the complete medium. Single
cell suspensions were confirmed under a microscope for
clonogenic assay. In addition, after 3 days of transfection, the
cell lysates were prepared for Western blot analysis.
Luciferase activity assay
PC3 PDGF-D cells with lower levels of let-7 were seeded at a
density of 6610
3 cells/well in a 96-well plate and incubated for
24 h. The cells were co-transfected with EZH2 39UTR luciferase
plasmid (Origene, Rockville, MD) or Renilla luciferase plasmid
and control miRNA, let-7a, let-7b, let-7c, and let-7d precursors
using DharmaFECT duo transfection reagent (DHARMACON,
Lafayette, CO). After 48 h of incubation, luciferase activity was
assayed using Steady–Glo Luciferase Assay System (Promega).
The Renilla luciferase activity was used as a control for
transfection efficiency.
Real-time RT-PCR
For determining mRNA levels, the total RNA from cells was
isolated using the RNeasy Mini Kit (Qiagen) and the DNA was
removed using an RNase-free NDase kit (Qiagen). One micro-
gram of RNA was reverse transcribed into cDNA using a High
Capacity RNA-to-cDNA Kit (Applied biosystems, Fostor, CA)
according to the manufacturer’s instruction. PCR was performed
as previously described [18]. The relative amount of mRNA was
normalized to the expression of GAPDH. For testing the miRNA
levels, the total RNA from cells was isolated using the miRNeasy
Mini Kit (Qiagen) and the DNA was removed using an RNase-
free NDase kit (Qiagen). 20 ng of RNA were reverse transcribed
into cDNA using a Universal cDNA Synthesis Kit (Exiqon,
Woburn, MA) according to the manufacturer’s instruction. Real
time PCR was performed using specific miRNA primers (Exiqon)
to quantify miRNA expression by using SYBRH Green RT-PCR
Reagents (Applied biosystems). The relative amount of miRNA
was normalized to the expression of RNU48. To determine the
mRNA or miRNA levels in prostate cancer patient tissues, the
total RNA was isolated from FFPE tissues using miRNeasy FFPE
Kit (Qiagen) according to the manufacturer’s instruction. RT-
PCR assay for the miRNA and mRNA expression was assessed as
above. The relative amount of mRNA was normalized to the
expression of beta-actin and relative amount of miRNA was
normalized to the expression of RNU1A.
Microarray for miRNA profile in prostate cancer patient
tissues
miRNA microarray as well as data analysis were conducted
following procedures as previously described by Kong et al [18].
All data is MIAME compliant and that the raw data has been
deposited in a MIAME compliant database. GEO accession
number is GSE34310.
Statistical methods
Experiments presented in the figures for cell line studies are
representative of three or more independent repetitions. The data
are presented as the mean and standard deviation (SD) in the bar
charts. The miRNA and mRNA data from patient tissue specimen
was log transformed before analysis. Comparisons of the
continuous variables between two independent groups were made
using the Wilcoxon rank sum test. For paired related groups (i.e.
Normal tissues and paired G6 tumor tissues), the Wilcoxon signed
rank test was used. Spearman correlations were used to describe
the strength of linear relationship between two variables. Statistical
test of significance of the correlation was based on approximated t
distribution. All statistical tests were two sided at significance level
of 0.05 unless otherwise specified. To reduce the false positivity, in
other words control the family-wise Type I error, in this
preliminary early phase exploratory study, we used adjusted p
values from the two-stage step-up false discovery rate (FDR)
controlling method [36]. A nominal error rate for estimating the
number of true null hypotheses in the two-stage FDR procedure
was set at 0.05.
Results
Expression of the let-7 family was lost in prostate cancer
(PCa) tissue specimens
To determine the levels of the let-7 family in PCa tissue
specimens, we collected pre-treatment PCa tissues and matched
adjacent normal tissue specimens (used as control for comparison
with tumor tissues). The results from miRNA expression by
mircroarray expression profiling showed that all the members of
the let-7 family (miR-98 was undetectable) decreased in the PCa
tissues compared to adjacent normal tissue specimens (Fig. 1A).
Moreover, we found that the expression of let-7a, let-7b, let-7c and
let-7d were accurately measurable compared to other family
members because their expressions were very low (Fig. 1A).
Therefore, we have determined and confirmed the expressions of
let-7a, let-7b, let-7c, and let-7d in all the cases including 129 PCa
tissue specimens and 94 adjacent normal tissue specimens. We
discovered that the expression of the let-7 family in histologically
normal prostate tissues from Gleason grade 7 or higher tumor was
decreased compared to histologically normal tissue from Gleason
grade 6 tumors (data not shown), suggesting that the histologically
normal tissues from the prostate gland of patients with higher
grade tumors are not normal. Thus, we took normal from the
prostate of all patients diagnosed with grade 6 tumors for further
analysis and used that as ‘‘normal tissue control’’. We observed
that the expressions of the let-7 family in grade 6 tumors are not
statistically different compared to normal control. However, we
found a significantly decreased expression of let-7a, let-7b, let7c
and let-7d in PCa with Gleason grade 7 or higher tumors
compared to normal tissue control (Fig. 1B). These results suggest
that the loss of let-7 family could be associated with PCa
aggressiveness especially because the lower grade tumors were
no different from the normal tissue control, whereas higher grade
tumors were different.
Expression of EZH2 was increased in PCa tissue
specimens and was inversely correlated with the
expression of the let-7 family
Since the expression of the let-7 family was lost in PCa tissues of
patients with higher Gleason grade, it raises a question of how the
let-7 family could regulate PCa aggressiveness. We have searched
targets of the let-7 family using TargetScan software and we found
that EZH2 could be regulated by the let-7 family because there is a
specific binding site in the 39UTR of EZH2 mRNA. Thus, we
have assessed the expression of EZH2 mRNA in PCa tissues. Our
results showed that EZH2 expression was increased in PCa tissue
specimens with Gleason grade 7 and higher compared with
normal tissue control (Fig. 1C). The expression of let-7b and let-7c
was inversely correlated with EZH2 expression with r=20.36
(95% CI: 20.61 to 20.06), p=0.0414 and r=20.43 (95% CI:
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suggest that the loss of let-7 could be responsible for increased
expression of EZH2.
Let-7 repressed EZH2 expression and inhibited
clonogenic growth of PCa cells
We examined the expression of EZH2 in PCa cell lines and
immortalized prostate epithelial cell lines, and found that EZH2
was expressed in prostate cancer cells at relatively higher levels
compared to immortalized prostate epithelial cell lines: PZ-HPV-7
and RWPE-1 cells (Fig. 2A, upper panel). To further determine
the biological consequence of the let-7 family expression in the
regulation of EZH2 expression, we transfected PC3 and PC3
PDGD-D cells with let-7 precursors, and the results showed that
let-7 family members could significantly inhibit the expression of
EZH2 in these two cell lines (Fig. 2A, middle and lower panel).
These results suggest that let-7 family regulates the expression of
EZH2. In order to gain further mechanistic insight, we tested
whether let-7 could directly repress the expression of EZH2 by
binding to 39UTR of EZH2 mRNA. We co-transfected EZH2
39UTR luciferase plasmid and let-7 precursors, and found that let-
7a, let-7b, let-7c, and let-7b could strongly inhibit EZH2 39UTR
Figure 1. Loss of the let-7 family inversely correlated with increased expression of EZH2 in PCa tissue specimens compared to
adjacent normal prostate tissues. (A) Microarray profiling was done for assessing the expression of miRNA using total RNA extracted from three
PCa tissue specimens and matched adjacent normal prostate tissues. The results showed that let-7a, let-7b, let-7c and let-7d was highly expressed in
prostate tissues and their expression was lost in human PCa tissue specimens (* p,0.05, ** p,0.01). (B) The results from real time-RT-PCR confirmed
that the levels of let-7b, let-7c and let-7d were significantly down-regulated in tumors with higher Gleason grade. (7a: let-7a; N: normal; TG6: tumor
tissues from patients with Gleason grade 6. n=39 for normal, n=44 for TG6, n=52 for TG7, n=33 for TG8, 9). (C) A significant up-regulation of the
expression of EZH2 was observed in PCa tissue specimens with Gleason grade 7 (n=46) and higher (n=33), but not in PCa specimens with Gleason
grade 6 (n=39). (D) EZH2 levels were inversely correlated with let-7b and let-7c expressions in tumor specimens with Gleason grade 7.
doi:10.1371/journal.pone.0033729.g001
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miRNA (Fig. 2B). The let-7 binding sites in the 39UTR of EZH2
mRNA are shown in Figure 2C. We then tested the biological
consequence of cells transfected with pre-let-7 family and assessed
clonogenic growth as an indirect in vitro measure of tumor
aggressiveness. We found that the overexpression of let-7 family
significantly inhibited the clonogenic growth of PC3 PDGF-D
cells, which initially showed lower expression of let-7 (Fig. 2D).
However, currently there is no method that could be clinically
useful for the upregulation of lost miRNAs. To that end, we tested
our hypothesis by testing whether BR-DIM could be useful for the
upregulation of miRNAs.
BR-DIM treatment led to the upregulation of the let-7
family and consequently down-regulated the expression
of EZH2 in PCa cells
In the present study, we found that BR-DIM treatment
increased the expression of let-7 family in several PCa cell lines
including LNCaP, C4-2B and PC3 cells (Fig. 3A and Fig. S1A–C).
Moreover, BR-DIM treatment also led to decreased expression of
EZH2 mRNA (Fig. 3B) and protein in different PCa cell lines and
at different time points (Fig. 3C, 3D and Fig. S1D). Moreover,
More interestingly, the data from our on-going phase II clinical
trial showed that BR-DIM treatment of PCa patients prior to
Figure 2. Let-7 regulated EZH2 expression, and inhibited clonogenic growth capacity of PCa cell lines. (A) Expression of EZH2 was
found to be higher in PCa cell lines compared with immortalized prostate epithelial cell lines: PZ-HPV-7 and RWPE-1 (upper panel) and transfection of
let-7 precursors inhibited EZH2 expression in PC3 and PC3 PDGF-D cells 3 days after transfection (middle and lower panel). (B) let-7 family members
repressed EZH2 39UTR luciferase activity in PC3 PDGF-D cells (lower levels of let-7 family in these cells) co-transfected with let-7 and EZH2 39UTR
luciferase plasmid. (C) let-7 binding sites in the 39UTR of EZH2 mRNA were shown. (D) Transfection of let-7 precursors significantly reduced
clonogenic growth capacity of PC3 PDGF-D cells (Con: control, 7a: pre-let-7a, ** p,0.01).
doi:10.1371/journal.pone.0033729.g002
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7b, let-7c, and let-7d in tumor specimens after BR-DIM
intervention (Fig. 4A–C), and these results are consistent with
decreased expression of EZH2 (Fig. 4D). Therefore, our results
suggest that BR-DIM could be an important agent to re-express
the lost miRNAs especially the let-7 family, which would reduce
the level of EZH2 expression and compromise CSCs or CSLCs
function.
BR-DIM treatment inhibited self-renewal and clonogenic
capacity of PCa cells
To test whether BR-DIM could regulate the self-renewal
capacity and clonogenic ability of PCa cells, we performed
sphere-forming assays and found that the treatment of C4-2B and
PC3 PDGF-D cells with 10 or 25 mM BR-DIM markedly reduced
the number and the size of prostaspheres compared to untreated
control (DMSO control) (Fig. 5A). Moreover, BR-DIM treatment
also inhibited the clonogenic growth capacity of PCa cell lines C4-
2B and PC3 PDGF-D cells (Fig. 5B). The results from soft agar
assay further showed that the treatment of C4-2B cells with 10 or
25 mM BR-DIM reduced the colony size and numbers (Fig. 5C
and 5D), suggesting that BR-DIM could eliminate tumor cells
especially the cells with CSCs or CSLCs characteristics by up-
regulating let-7 family and consequently by down-regulating the
expression of EZH2.
Discussion
Although it is known that the let-7 family is associated with
maintenance of stem cell signature, which is believed to be strongly
linked with cancer recurrence, the mechanism by which let-7
family regulates the stem cell signatures is unknown. In this study,
we found that the expression of the let-7 family was lost in PCa
tissue specimens with Gleason grade 7 or higher but not in patients
with Gleason grade 6 tumors. These results were consistent with
corresponding increased expression of EZH2, which appears to be
a target of the let-7 family. Our results suggest that the loss of
expression of let-7 with a consequent over-expression of EZH2
could be associated with PCa aggressiveness. Moreover, the results
from 39UTR of the EZH2 luciferase assay and Western blot
analysis further confirmed that let-7 could repress EZH2
expression by binding to 39UTR element of EZH2 mRNA.
Recent studies have shown that miR-101 negatively regulates
the expression of EZH2 [37]. Our data suggest that the let-7
family of miRNAs also be responsible for the regulation of EZH2
Figure 3. BR-DIM treatment increased let-7 and consequently reduced EZH2 expression. (A) Total RNA was isolated from LNCaP, C4-2B
and PC3 cells treated with 25 mM BR-DIM for 24 h and the results from real time RT-PCR showing that the expression of let-7 was increased following
BR-DIM treatment compared to untreated control (c: DMSO control). (B) Levels of EZH2 mRNA were repressed by BR-DIM treatment in a dose
dependent meaner. (C and D) The cell lysates were prepared from cells treated with BR-DIM for 48 h and Western blot showing the protein levels of
EZH2, which was down-regulated by BR-DIM treatment (PC3 PD: PC3 PDGF-D cells, *, p,0.05; **, p,0.01).
doi:10.1371/journal.pone.0033729.g003
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let-7a, let-7b, let-7c and let-7d are highly expressed in human
normal prostate tissue specimens and their expression was lost in
PCa tissues, especially, in patients with aggressive (higher Gleason
grade tumors) tumors. Notably, we found that the expression of
let-7a, let-7b, let-7c, and let-7d was decreased in normal prostate
tissues from Gleason grade 7 and higher compared with normal
tissues obtained from patients with Gleason grade 6. These results
suggest that the normal prostate tissues obtained from patients
with higher Gleason grade tumors are not normal, which is
consistent with a field-effect of prostate carcinogenesis [38].
EZH2 is a component of the PRC2, which mediates chromatin-
based gene silencing through trimethylation of lysine 27 on histone
H3. PRC2 also plays a critical role in the maintenance of the
embryonic and adult stem cells [24,25] as well as playing a critical
role in tumor initiation and progression [26,39]. Over-expression
of EZH2 has been found to be strongly linked with the acquisition
of EMT phenotype because PRC2 inhibits E-cadherin expression
through trimethylation of H3 lysine 27 [28,29,40]. Moreover,
EZH2 directly regulates DNA methylation by serving as a
recruitment platform for DNA methyltransferase (DNMT)
through binding of DNMTs to several EZH2-repressed genes
[30], and methylation of the E-cadherin gene promoter has been
demonstrated to correlate with progression of PCa [41]. DNA
methylation profiles of the E-cadherin promoter were further
assessed in the NCI-60 panel of cancer cells. Of the NCI-60 cancer
cells, the 38 epithelial cell lines showed significantly lower (28%)
methylation levels compared with the nonepithelial cell lines (58%)
derived from invasive or metastatic cancer [42]. In addition,
methylation mediated loss of the miR-200 family leads to E-
cadherin expression as documented earlier [43,44]. Interestingly,
recent studies have shown that EZH2 inhibits the expression of the
miR-200 family and miR-203 through trimethylation of H3 lysine
27 [45]. Loss of the miR-200 family and miR-203 is believed to be
associated with EMT and stem cell signatures [18,46–48].
Therefore, EZH2 could contribute to cancer progression and
recurrence by regulating and maintaining EMT and stem cell
signatures through methylation of target gene promoter and
trimethylation of H3 lysine 27.
In the current study, we found that the levels of EZH2 were
increased in PCa tissue specimens, especially in patients with
higher Gleason grade tumors and were also highly expressed in
PCa cell lines, suggesting that the over-expression of EZH2 is
associated with PCa aggressiveness. Therefore, finding novel
approaches by which one could re-express the lost miRNAs such
as let-7 family with consequent down-regulation of EZH2 could
become a newer avenue for the prevention of PCa and/or
treatment of aggressive PCa. To that end, we tested the effects of
BR-DIM (B-DIM), which is a ‘‘natural agent’’-derived compound
(formulated DIM: 3,39-diindolylmethane by BioResponse, Boul-
Figure 4. BR-DIM intervention in PCa patients resulted in the increased expression of let-7 family and consequently inhibited EZH2
expression in tumor tissues. RNA was obtained from BR-DIM intervention clinical trial samples where BR-DIM was given to patients for 2–4 weeks
prior to surgery. RNA was also obtained from formalin-fixed paraffin-embedded (FFPE) tissue specimens of PCa patients with matched tumor Gleason
grade, tumor stage and patient age as control group. The expression of miRNAs and mRNA was assessed using real time RT-PCR. Relative miRNA and
mRNA levels were normalized to RNU1A1 and beta-actin, respectively. (A) BR-DIM intervention led to the increased trend in levels of Let-7a
expression. (B and C) let-7b, let-7c and let-7d were significantly up-regulated by BR-DIM intervention. (D) EZH2 expression was down-regulated by BR-
DIM intervention.
doi:10.1371/journal.pone.0033729.g004
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mice have been reported [49] and a pharmacokinetic comparison
was also reported between BR-DIM and unformulated DIM [50]
showing that BR-DIM exhibits 50–60% greater bioavailability
than the crystalline formulation in all tissues studied (plasma, liver,
kidney, lung, heart and brain). Moreover, our phase I clinical trial
results of BR-DIM in PCa patients showed that it is safe [31],
which eventually led to our currently on-going phase II clinical
trial in PCa patients prior to radical prostatectomy. The results
obtained from eleven tumor specimens from this phase II clinical
trial are exciting because it showed, for the first time, that let-7
miRNAs could be upregulated in tumors by BR-DIM intervention
with consequent down-regulation of EZH2. Therefore, BR-DIM
intervention could become a newer therapeutic approach since
BR-DIM could cause targeted elimination of EMT phenotypic
cells or CSCs (CSLCs) that contribute to tumor recurrence and
metastasis as seen in patients with mCRPC. However, sample size
is relatively small from our on-going clinical trial of BR-DIM
intervention, and thus the effects of BR-DIM on molecular
biomarkers will needs further investigation using larger number of
patients to make definitive conclusion. The impact of these ‘‘proof-
of-concept’’ findings will be further confirmed upon the comple-
tion of our on-going phase II clinical trial.
In summary, we found that BR-DIM up-regulated the
expression of the let-7 family and consequently down-regulated
the expression of EZH2 not only in PCa cell lines but also in
human PCa tissue specimens from our on-going phase II clinical
trial. These results suggest that BR-DIM could serve as a novel
agent for the inhibition of PCa progression and recurrence.
Supporting Information
Figure S1 BR-DIM treatment upregulated let-7 expres-
sion and consequently reduced EZH2 expression in
LNCaP cells at different time points. (A–C) Total RNA
was isolated from LNCaP cells treated with 25 mM BR-DIM for 8,
16 and 24 h, and the results from real time RT-PCR were shown
to document the expression of let-7, which was increased following
Figure 5. BR-DIM treatment inhibited clonogenic growth and prostasphere-forming ability. (A) Single cell suspensions of C4-2B and PC3
PDGF-D cells were plated in ultra low adherent wells of 6-well plate at 2000 cells/well in DMEM/F12 supplemented with B27 and N2 and with 10,
25 mM BR-DIM and incubated for 6 days. Prostasphere numbers were reduced by BR-DIM treatment (upper panel). Prostaspheres were photographed
and the results showed that 10 and 25 mM BR-DIM significant reduced the size of prostaspheres (lower panel). (B) C4-2B and PC3 PDGF-D cells were
seeded in 100 mm dishes at 2000 cells/dish, after 24 h incubation, the cells were treated with 10 or 25 mM BR-DIM for 72 h and then the culture
medium was changed with fresh media without BR-DIM for every 3 days. After 2 weeks, the colonies were stained and photographed. (C and D) Soft
agar assay showed that BR-DIM treatment reduced the size (left panel) and the numbers of colonies of C4-2B cells (right panel; **, p,0.01).
doi:10.1371/journal.pone.0033729.g005
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control). (D) The cell lysates were prepared from LNCaP cells
treated with BR-DIM for 24, 48 and 72 h. BR-DIM treatment
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